INVESTER I TAKARA BIO MED ENDAVU: Køb Takara Bio ($TF2) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Takara Bio, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Takara Bio Inc. is a leading biotechnology company specializing in the development and marketing of genetic engineering technologies and life science solutions. Established in 2002 as a spin-off from Takara Shuzo, it provides a comprehensive range of products and services for basic research, industrial applications, and advanced therapeutic development, including reagents for polymerase chain reaction (PCR), gene amplification, next-generation sequencing, DNA/RNA purification, cloning, genome editing tools like CRISPR/Cas systems, and scientific instruments such as mass spectrometry and single-cell analysis platforms. The company supports regenerative medicine through contract development and manufacturing organization (CDMO) services, including cell processing, vector production, and quality testing at facilities like the Center for Gene and Cell Processing in Kusatsu, Shiga, Japan. Takara Bio Inc. advances gene therapy for cancers, such as oncolytic virus C-REV for malignant melanoma and engineered T-cell therapies for synovial sarcoma, alongside genetic analysis services. With a global network including subsidiaries in the U.S., Europe, China, and Sweden, and over 1,500 employees, it serves academic institutions, pharmaceutical firms, and biotech companies, driving innovation in molecular biology, precision medicine, and biopharmaceutical research. Headquartered in Kusatsu, Japan, Takara Bio Inc. traces its roots to 1967 in biomedical business and continues to expand through strategic acquisitions and technological advancements.